Navigation Links
QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
Date:2/10/2010

Evaluate Analgesic Efficacy and Safety of MoxDuo(TM)IR in Patients with Moderate to Severe Post-Operative Pain Following Total Knee Replacement Surgery

SYDNEY and BEDMINSTER, N.J., Feb. 10 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.  This two-arm study will compare the effectiveness and safety of a flexible MoxDuo™IR dose regimen to a fixed low dose for managing moderate to severe pain in patients who have undergone total knee replacement surgery.  The Company expects to complete dosing in Q3 2010 in preparation for filing a New Drug Application (NDA) with the US Food and Drug Administration in Q4 2010. MoxDuo™IR targets the acute pain market, a $2.5 billion segment of over $7 billion spent annually on prescription opioids in the US.

"In support of our Phase 3 program, clinical trials conducted to date have consistently demonstrated MoxDuo™IR achieves as good or better pain relief with fewer incidences of moderate-severe side effects than morphine, oxycodone or Percocet®. Based on these data, we are optimistic about the competitive advantages of MoxDuo," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.  "With the initiation of the Company's second pivotal trial for MoxDuo™IR, we are one step closer to definitively proving the value of our Dual-Opioid™ product to potential partners, prescribers and patients."

In 2009, an open-label pilot study demonstrated improved analgesia of flex
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... -- Tom Daulton, CEO of Mammotome, a division of Devicor Medical ... Cincinnati chapter of the Association for ... top executive who is also a breast cancer survivor, led ... March of 2010. Daulton will be presented with the award ... Bank, on May 22. The ACG Deal Maker ...
(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... 2013  Armada Health Care (Armada) is pleased ... corporate website ( www.armadahealthcare.com ).  This new website ... first-to-market services and its position as the leading ... pharmacy industry. The updated website visibly ... model in delivering an extensive portfolio of services ...
Breaking Medicine Technology:Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2
... Toll-Like Receptor 3 (TLR3) Agonist, SAN DIEGO, ... announced that the company has developed a,proprietary vaccine ... for use in both therapeutic and prophylactic vaccines., ... a Toll-like Receptor 3 (TLR3) agonist that when ...
... N.C., June 18 Pilot Therapeutics,Holdings, Inc. ... as Gene,Smart(TM) Health., (Logo: http://www.newscom.com/cgi-bin/prnh/20080618/CLW006LOGO ... gene-based nutrition, Gene Smart(TM) Health uniquely,combines breakthrough ... health, food, nutrition, and wellness markets to ...
Cached Medicine Technology:Nventa Develops Proprietary Vaccine Adjuvant 2Nventa Develops Proprietary Vaccine Adjuvant 3Nventa Develops Proprietary Vaccine Adjuvant 4Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health 2
(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...
(Date:5/21/2013)... Modern couples have countless strains ... Counseling’s Sexuality and Relationship Workshops, couples are learning ... healthier habits for their relationship. There are both ... and individuals at Texas Counseling. Their goal is ... skills to develop long term solutions. , ...
(Date:5/21/2013)... of Defense Serum Repository (DoDSR), University of Cincinnati (UC) ... bowel disease (IBD), which could help with earlier diagnosis ... symptoms. , This finding, the first of its kind ... presented via podium presentation by staff from Walter Reed ... being held May 18-21 in Orlando, Fla. , ...
(Date:5/21/2013)... The Las Vegas personal injury law firm Benson, ... Gates, a senior at Coronado High School, is the winner ... . As the winner of the essay contest, Crawford received ... Dec. 1, 2012 and ran through April 30th, 2013. Participating ... minimum essay on “The Role of the civil tort system.” ...
(Date:5/21/2013)... A new study appearing in the current issue ... harvested from fat (adipose) are more potent than those ... body’s immune system. , The finding could have ... tissue-derived stem cells (AT-SCs) are far more plentiful in ... can be collected from waste material from liposuction procedures. ...
Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3
... PARK, Md., June 5 Dynasplint Systems, Inc. --, ... 34th annual,Severna Park Independence Day Parade and Festival. Held ... at St. Martin,s -in-the-field and,Our Shepherd Lutheran churches on ... and family activities at Cypress Creek Park., This ...
... Predicts Growing Opposition on Capitol Hill Once Negative Impact ... June 5 In thanking U.S.,Senators Kent Conrad (D-ND), ... (D-ND) and Shelley Moore Capito (R-WV) for leading a,new ... plan to,cut by regulatory means $770 million in seniors, ...
... Ind., June 5 Hill-Rom (NYSE: HRC ... Award for the,TotalCare(R) Bariatric Plus therapy system. The ... This is the second year in a row,that ... award., The TotalCare Bariatric Plus therapy system ...
... also provides business update, including fourth-quarter fiscal 2008 ... ... Iowa, June 5 Meredith Corporation,(NYSE: MDP ), one of ... Communications, a leading healthcare,marketing communications firm. Additionally, the company provided a,business ...
... to reject unfair offer, study shows , , THURSDAY, June 5 ... serotonin govern the way people react to unfair offers when ... , Serotonin, which carries messages between neurons, is involved in ... anger in women was affected by variations in a gene ...
... apparently solved a long-standing frustration in creating certain synthetic molecules ... with fewer side effects. , Like human hands, many molecules ... left. But usually only one of the two versions has ... sometimes even harmful. For example, side effects from the morning ...
Cached Medicine News:Health News:Front Line Caregiver Coalition Thanks Sens. Conrad, Coleman and Reps. Pomeroy, Capito and Berkley for Leading Bipartisan Hill Effort to Stop Bush Administration's Damaging Medicare Cuts 2Health News:Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award 2Health News:Hill-Rom Innovative TotalCare(R) Bariatric Plus Therapy System Receives Gold Medical Device Excellence Award 3Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 2Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 3Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 4Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 5Health News:Serotonin Levels Determine Sense of Fairness 2Health News:Duke chemist has new way to tell right from left 2
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... Unique product designed for LASIK surgery ... Designed to irrigate the corneal interface ... easy insertion under the flap and ... ports provide multi-directional irrigation.27G x 7/8in ...
Medicine Products: